Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Witjes

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
European Urology|February 21, 1998
Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flowW P Witjes, J J de la Rosette, M Zerbib, et al.
British Journal of Urology|November 1, 1996
Clinical implications of the rise and fall of prostate specific antigen after laser prostatectomyM P van Iersel, C M Thomas, W P Witjes, et al.
The Journal of Urology|September 1, 1996
Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargementW P Witjes, M J de Wildt, P F Rosier, et al.
World Journal of Urology|May 6, 2020
Quality of life with pharmacological treatment in patients with benign prostatic enlargement: results from the Evolution European Prospective Multicenter Multi-National Registry StudyNikita R Bhatt, Niall F Davis, W P Witjes, et al.
Urology|September 8, 1998
Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative GroupJ A Witjes, A P v d Meijden, L Collette, et al.
European Urology|September 10, 1998
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study GroupF M Debruyne, A Jardin, D Colloi, et al.
Progress in Clinical and Biological Research|January 1, 1992
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The NetherlandsW P Witjes, P M van der Meijden, E P Roos, et al.
The Journal of Urology|April 1, 1996
Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasiaW P Witjes, F W Rosier, M J de Wildt, et al.
European Urology|November 24, 1999
Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study GroupW P Witjes, M König, F P Boeminghaus, et al.
World Journal of Urology|October 17, 2020
Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registryNikita R Bhatt, Niall F Davis, W P Witjes, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
European Urology|February 21, 1998
Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flowW P Witjes, J J de la Rosette, M Zerbib, et al.
British Journal of Urology|November 1, 1996
Clinical implications of the rise and fall of prostate specific antigen after laser prostatectomyM P van Iersel, C M Thomas, W P Witjes, et al.
The Journal of Urology|September 1, 1996
Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargementW P Witjes, M J de Wildt, P F Rosier, et al.
World Journal of Urology|May 6, 2020
Quality of life with pharmacological treatment in patients with benign prostatic enlargement: results from the Evolution European Prospective Multicenter Multi-National Registry StudyNikita R Bhatt, Niall F Davis, W P Witjes, et al.
Urology|September 8, 1998
Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative GroupJ A Witjes, A P v d Meijden, L Collette, et al.
European Urology|September 10, 1998
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study GroupF M Debruyne, A Jardin, D Colloi, et al.
Progress in Clinical and Biological Research|January 1, 1992
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The NetherlandsW P Witjes, P M van der Meijden, E P Roos, et al.
The Journal of Urology|April 1, 1996
Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasiaW P Witjes, F W Rosier, M J de Wildt, et al.
European Urology|November 24, 1999
Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study GroupW P Witjes, M König, F P Boeminghaus, et al.
World Journal of Urology|October 17, 2020
Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registryNikita R Bhatt, Niall F Davis, W P Witjes, et al.
Pageof 5